-
Je něco špatně v tomto záznamu ?
In Vivo Performance and Properties of Tamoxifen Metabolites for CreERT2 Control
A. Felker, S. Nieuwenhuize, A. Dolbois, K. Blazkova, C. Hess, LW. Low, S. Burger, N. Samson, TJ. Carney, P. Bartunek, C. Nevado, C. Mosimann,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
Public Library of Science (PLoS)
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2006-12-01
Open Access Digital Library
od 2006-10-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2008-01-01
Nursing & Allied Health Database (ProQuest)
od 2006-12-01
Health & Medicine (ProQuest)
od 2006-12-01
Public Health Database (ProQuest)
od 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
- MeSH
- buněčné linie MeSH
- časové faktory MeSH
- dánio pruhované MeSH
- integrasy genetika MeSH
- lidé MeSH
- receptory pro estrogeny chemie genetika MeSH
- rekombinace genetická účinky léků MeSH
- rekombinantní fúzní proteiny chemie genetika MeSH
- stabilita léku MeSH
- stereoizomerie MeSH
- tamoxifen analogy a deriváty chemie metabolismus farmakologie MeSH
- terciární struktura proteinů MeSH
- vysoká teplota MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Mutant Estrogen Receptor (ERT2) ligand-binding domain fusions with Cre recombinase are a key tool for spatio-temporally controlled genetic recombination with the Cre/lox system. CreERT2 is efficiently activated in a concentration-dependent manner by the Tamoxifen metabolite trans-4-OH-Tamoxifen (trans-4-OHT). Reproducible and efficient Cre/lox experimentation is hindered by the gradual loss of CreERT2 induction potency upon prolonged storage of dissolved trans-4-OHT, which potentially results from gradual trans-to-cis isomerization or degradation. Here, we combined zebrafish CreERT2 recombination experiments and cell culture assays to document the gradual activity loss of trans-4-OHT and describe the alternative Tamoxifen metabolite Endoxifen as more stable alternative compound. Endoxifen retains potent activation upon prolonged storage (3 months), yet consistently induces half the ERT2 domain fusion activity compared to fresh trans-4-OHT. Using 1H-NMR analysis, we reveal that trans-4-OHT isomerization is undetectable upon prolonged storage in either DMSO or Ethanol, ruling out isomer transformation as cause for the gradual loss of trans-4-OHT activity. We further establish that both trans-4-OHT and Endoxifen are insensitive to light exposure under regular laboratory handling conditions. We attribute the gradual loss of trans-4-OHT potency to precipitation over time, and show that heating of aged trans-4-OHT aliquots reinstates their CreERT2 induction potential. Our data establish Endoxifen as potent and reproducible complementary compound to 4-OHT to control ERT2 domain fusion proteins in vivo, and provide a framework for efficient chemically controlled recombination experiments.
CZ OPENSCREEN Institute of Molecular Genetics of the ASCR v v i Prague Czech Republic
Department of Chemistry University of Zürich Zürich Switzerland
Institute of Molecular and Cell Biology A*STAR Biopolis Drive Singapore Singapore
Institute of Molecular Life Sciences University of Zürich Zürich Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16027545
- 003
- CZ-PrNML
- 005
- 20161005132136.0
- 007
- ta
- 008
- 161005s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0152989 $2 doi
- 024 7_
- $a 10.1371/journal.pone.0152989 $2 doi
- 035 __
- $a (PubMed)27077909
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Felker, Anastasia $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
- 245 10
- $a In Vivo Performance and Properties of Tamoxifen Metabolites for CreERT2 Control / $c A. Felker, S. Nieuwenhuize, A. Dolbois, K. Blazkova, C. Hess, LW. Low, S. Burger, N. Samson, TJ. Carney, P. Bartunek, C. Nevado, C. Mosimann,
- 520 9_
- $a Mutant Estrogen Receptor (ERT2) ligand-binding domain fusions with Cre recombinase are a key tool for spatio-temporally controlled genetic recombination with the Cre/lox system. CreERT2 is efficiently activated in a concentration-dependent manner by the Tamoxifen metabolite trans-4-OH-Tamoxifen (trans-4-OHT). Reproducible and efficient Cre/lox experimentation is hindered by the gradual loss of CreERT2 induction potency upon prolonged storage of dissolved trans-4-OHT, which potentially results from gradual trans-to-cis isomerization or degradation. Here, we combined zebrafish CreERT2 recombination experiments and cell culture assays to document the gradual activity loss of trans-4-OHT and describe the alternative Tamoxifen metabolite Endoxifen as more stable alternative compound. Endoxifen retains potent activation upon prolonged storage (3 months), yet consistently induces half the ERT2 domain fusion activity compared to fresh trans-4-OHT. Using 1H-NMR analysis, we reveal that trans-4-OHT isomerization is undetectable upon prolonged storage in either DMSO or Ethanol, ruling out isomer transformation as cause for the gradual loss of trans-4-OHT activity. We further establish that both trans-4-OHT and Endoxifen are insensitive to light exposure under regular laboratory handling conditions. We attribute the gradual loss of trans-4-OHT potency to precipitation over time, and show that heating of aged trans-4-OHT aliquots reinstates their CreERT2 induction potential. Our data establish Endoxifen as potent and reproducible complementary compound to 4-OHT to control ERT2 domain fusion proteins in vivo, and provide a framework for efficient chemically controlled recombination experiments.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a stabilita léku $7 D004355
- 650 _2
- $a vysoká teplota $7 D006358
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a integrasy $x genetika $7 D019426
- 650 _2
- $a terciární struktura proteinů $7 D017434
- 650 _2
- $a receptory pro estrogeny $x chemie $x genetika $7 D011960
- 650 _2
- $a rekombinantní fúzní proteiny $x chemie $x genetika $7 D011993
- 650 _2
- $a rekombinace genetická $x účinky léků $7 D011995
- 650 _2
- $a stereoizomerie $7 D013237
- 650 _2
- $a tamoxifen $x analogy a deriváty $x chemie $x metabolismus $x farmakologie $7 D013629
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a dánio pruhované $7 D015027
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Nieuwenhuize, Susan $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
- 700 1_
- $a Dolbois, Aymeric $u Department of Chemistry, University of Zürich, Zürich, Switzerland.
- 700 1_
- $a Blazkova, Kristyna $u CZ-OPENSCREEN, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
- 700 1_
- $a Hess, Christopher $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
- 700 1_
- $a Low, Larry W L $u Institute of Molecular and Cell Biology (IMCB), A*STAR, Biopolis Drive, Singapore, Singapore.
- 700 1_
- $a Burger, Sibylle $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
- 700 1_
- $a Samson, Natasha $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
- 700 1_
- $a Carney, Tom J $u Institute of Molecular and Cell Biology (IMCB), A*STAR, Biopolis Drive, Singapore, Singapore. Lee Kong Chian School of Medicine, Nanyang Technological University, 50 Nanyang Avenue, Singapore, Singapore.
- 700 1_
- $a Bartunek, Petr $u CZ-OPENSCREEN, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
- 700 1_
- $a Nevado, Cristina $u Department of Chemistry, University of Zürich, Zürich, Switzerland.
- 700 1_
- $a Mosimann, Christian $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 4 (2016), s. e0152989
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27077909 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161005132523 $b ABA008
- 999 __
- $a ok $b bmc $g 1165859 $s 952175
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 11 $c 4 $d e0152989 $e 20160414 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20161005